REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 144 filers reported holding REVANCE THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.20 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2020 | $1,099,000 | -67.8% | 45,000 | -79.1% | 0.01% | -68.4% |
Q1 2020 | $3,411,000 | -2.2% | 215,000 | 0.0% | 0.04% | +2.7% |
Q4 2019 | $3,489,000 | +13.2% | 215,000 | -9.3% | 0.04% | -9.8% |
Q3 2019 | $3,081,000 | +0.7% | 237,000 | 0.0% | 0.04% | +7.9% |
Q2 2019 | $3,060,000 | -18.1% | 237,000 | 0.0% | 0.04% | -20.8% |
Q1 2019 | $3,735,000 | -21.7% | 237,000 | 0.0% | 0.05% | -34.2% |
Q4 2018 | $4,771,000 | +12.3% | 237,000 | +38.6% | 0.07% | +30.4% |
Q3 2018 | $4,249,000 | -9.5% | 171,000 | 0.0% | 0.06% | -24.3% |
Q2 2018 | $4,694,000 | -10.9% | 171,000 | 0.0% | 0.07% | -17.8% |
Q1 2018 | $5,267,000 | -2.4% | 171,000 | +13.2% | 0.09% | -3.2% |
Q4 2017 | $5,398,000 | +44.1% | 151,000 | +11.0% | 0.09% | +43.1% |
Q3 2017 | $3,747,000 | +1.4% | 136,000 | -2.9% | 0.06% | -5.8% |
Q2 2017 | $3,696,000 | +45.6% | 140,000 | +14.8% | 0.07% | +40.8% |
Q1 2017 | $2,538,000 | +83.0% | 122,000 | +82.1% | 0.05% | +53.1% |
Q4 2016 | $1,387,000 | – | 67,000 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Essex Woodlands Management, Inc. | 3,342,047 | $52,671,000 | 26.22% |
NovaQuest Capital Management, L.L.C. | 1,558,426 | $24,561,000 | 22.85% |
Sio Capital Management, LLC | 254,581 | $4,012,000 | 1.08% |
ArrowMark Colorado Holdings LLC | 3,409,217 | $53,729,000 | 0.51% |
Fosun International Ltd | 472,532 | $7,447,000 | 0.47% |
Rhenman & Partners Asset Management AB | 193,181 | $3,045,000 | 0.36% |
Phoenix Investment Adviser LLC | 4,900 | $77,000 | 0.17% |
HARBOURVEST PARTNERS LLC | 26,565 | $419,000 | 0.15% |
Quinn Opportunity Partners LLC | 56,672 | $893,000 | 0.12% |
MFN Partners Management, LP | 46,000 | $725,000 | 0.12% |